Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets 2013 Healthcare Conference

 Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets
                          2013 Healthcare Conference

PR Newswire

CALGARY, Feb. 25, 2013

CALGARY, Feb. 25, 2013 /PRNewswire/ - Dr. Matt Coffey, Chief Operating Officer
of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present at the 2013
RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at
3:35 p.m. ET.  The conference will take place on February 26^th and 27^th in
New York, NY.

A  live   audio  link   to   the  webcast   presentation  is   available   at: 
http://www.veracast.com/webcasts/rbc/healthcare2013/71114328.cfm  or  on   the 
company's website  at  http://www.oncolyticsbiotech.com/presentations.  It  is 
recommended that listeners log on 10 minutes in advance of the presentation to
register and download any necessary software.

An audio  replay  will be  accessible  approximately one  hour  following  the 
presentation on the Oncolytics website.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development
of oncolytic viruses  as potential cancer  therapeutics. Oncolytics'  clinical 
program includes a variety of human trials including a Phase III trial in head
and neck cancers using  REOLYSIN^®, its proprietary  formulation of the  human 
reovirus.  For   further   information   about   Oncolytics,   please   visit: 
www.oncolyticsbiotech.com.

The presentation and webcast times are subject to change. This release and the
presentation related thereto contain forward-looking statements which  involve 
known and unknown risks, delays, uncertainties and other factors not under the
Company's  control  and  which  may  cause  actual  results,  performance   or 
achievements of  the Company  to  be materially  different from  the  results, 
performance or expectations implied by these forward-looking statements.  Such 
risks and uncertainties include, among others,  the efficacy of REOLYSIN as  a 
cancer treatment, the success  and timely completion  of clinical studies  and 
trials,  uncertainties   related   to   the  research   and   development   of 
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's  quarterly and annual  filings with the  Canadian 
and U.S.  securities  commissions  for additional  information  on  risks  and 
uncertainties  relating  to  the  forward-looking  statements.  Investors  are 
cautioned against placing  undue reliance on  forward-looking statements.  The 
Company does not undertake to update these forward-looking statements,  except 
as required by applicable laws.

SOURCE Oncolytics Biotech Inc.

Contact:

The Equicom Group
Nick Hurst
300 5^th Ave. SW, 10^th Floor
Calgary, Alberta, T2P 3C4
Tel: 403.218.2835
Fax: 403.218.2830
nhurst@tmxequicom.com 

Dian Griesel, Inc.
Susan Forman
396 West Broadway, 2^nd Floor
New York, NY  10012
Tel:  212.825.3210
Fax:  212.825.3229
sforman@dgicomm.com